Zymergen, Inc.

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

Who: Ginkgo Bioworks, Boehringer Ingelheim What: The companies entered into a partnership in which they will mine Ginkgo’s database, which comprises three terabases of sequence data and more than 2

A drug developer went public in the US for the first time in more than two months when MAIA Biotechnology, Inc. raised $10m from the sale of 2 million shares at $5 each on 27 July, taking advantage

Two service providers with similar offerings for biopharmaceutical, industrial, cosmetic and agricultural clients – Ginkgo Bioworks and Zymergen, Inc. – will combine under one name as Ginkgo takes